EGFR and cancer prognosis.

By R. Nicholson, J. Gee, M. Harper. European Journal of Cancer, 2001

2,100 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/c2fe501bf6172554f79516b524cb0a4f98ace7f9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. N. Hynes
2. Thomas Holbro
3. J. Condeelis
4. Vincent A. Miller
5. Y. Yarden
6. J. Pollard
7. M. Lacouture
8. J. Baselga

In Pulmonary and Respiratory Medicine

1. Vincent A. Miller
2. N. Hynes

Citations in the corpus

• PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis (2012, neutral): “…revealed that activation of epidermal growth factor (EGF) receptor (EGFR), which has been reported in many human tumors (Moscatello et al., 1995; Nicholson et al., 2001; Wykosky et al., 2011), results in the translocation of PKM2, but not of PKM1, into the nucleus, where PKM2 binds to…”
• Kinase-targeted cancer therapies: progress, challenges and future directions (2018, background): “Elevated levels of the EGFR and HER-2 have been identified as common components of multiple cancer types and appear to promote solid tumor growth [200, 201].”
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. (2004, background): “High expression of EGFR has been associated with lower relapsefree and overall survival rates in several malignancies in retrospective studies [26].”
• ErbB receptors: directing key signaling networks throughout life. (2004, background): “associating its expression with reduced recurrence-free and overall survival in several cancer types, including SCCHN, ovarian, and others (96).”
• Triple-negative breast cancer--current status and future directions. (2009, result): “determination of activated versus total expression) [152], our results need to be substantiated before definite conclusions are possible.”
• Erlotinib in lung cancer - molecular and clinical predictors of outcome. (2005, neutral): “<5% 210 (65) 84 (67) 116 (66) 486 (67) ≥5% 99 (30) 34 (27) 47 (26) 213 (29) Data missing 16 (5) 7 (6) 14 (8) 32 (4)”
• Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium (2018, background): “The second class of small molecules directed to tyrosine kinase proteins was represented by Gefitinib (Iressa R ) and Erlotinib (Tarceva R ) both directed to the EGFR ATP-binding site and able to inhibit the abnormal activation of MAPK and PI3K/AKT pathways overexpressed in cancer cells (Nicholson e”
• Derailed endocytosis: an emerging feature of cancer (2008, background): “gov/cancertopics/types/lung">lung , ovary, colon and prostate, often indicating poor prognosi”
• Molecular mechanisms of invadopodium formation (2005, positive): “In many different cancer cell types the prognosis of a patient is inversely correlated with the overexpression and/or amplification of the EGF receptor family (Nicholson et al., 2001).”